Perspective Therapeutics (CATX) Net Cash Flow (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Net Cash Flow data on file, last reported at $23.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 235.92% year-over-year to $23.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.6 million (up 109.77% YoY), and the FY2025 full-year result was -$31.0 million, down 159.34% from the prior year.
• Net Cash Flow advanced to $23.3 million in Q1 2026, from $3.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $132.9 million in Q1 2024 to a low of -$164.9 million in Q4 2024.
• A 5-year average of -$2.9 million and a median of -$8.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 1834.75% in 2022 and soared 1451.13% in 2024, its largest moves.
• Tracing CATX's Net Cash Flow over 5 years: stood at -$34.9 million in 2022, then surged by 74.94% to -$8.7 million in 2023, then sank by 1785.23% to -$164.9 million in 2024, then surged by 102.35% to $3.9 million in 2025, then soared by 503.65% to $23.3 million in 2026.
• Business Quant data shows CATX's Net Cash Flow at $23.3 million in Q1 2026, $3.9 million in Q4 2025, and -$2.1 million in Q3 2025.